Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target.

Current pharmaceutical design - 1 Jan 2008

Porcellini E, Davis E J, Chiappelli M, Ianni E, Di Stefano G, Forti P, Ravaglia G, Licastro F

Abstract excerpt

alpha-1-antichymotrypsin (ACT), is an acute phase protein and a protease inhibitor produced by the liver and brain. ACT is involved in the pathogenesis of Alzheimer's disease (AD), since elevated ACT concentration was found in cerebrospinal fluid (CSF) and brain from AD. ACT has also been shown t...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to alpha 1-Antichymotrypsin
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoprotein E4

Share to Cognition Disorders

Share to Drug Delivery Systems

Share to Enzyme-Linked Immunosorbent Assay

Share to Severity of Illness Index

Source

Identifiers

PMID: 18991685
DOI: 10.2174/138161208786264151

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18991685-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target.PMID 18991685Read ↗

Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.Semantic proximity Read ↗

Plasma alpha1-antichymotrypsin in Alzheimer's disease; relationships with APOE genotypes.Semantic proximity Read ↗

A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease.Semantic proximity Read ↗

Blood levels of alpha-1-antichymotrypsin and risk factors for Alzheimer's disease: effects of gender and apolipoprotein E genotype.Semantic proximity Read ↗

Post-stroke dementia is associated with alpha(1)-antichymotrypsin polymorphism.Semantic proximity Read ↗

Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease.Semantic proximity Read ↗

Alpha-1-antichymotrypsin polymorphism in schizophrenia: frequency, age at onset and cognitive function.Semantic proximity Read ↗

Increased frequency of the alpha-1-antichymotrypsin T allele in cerebral amyloid angiopathy.Semantic proximity Read ↗

No association between alpha-1-antichymotrypsin polymorphism and Alzheimer's disease in Chinese.Semantic proximity Read ↗

Absence of association of alpha1-antichymotrypsin polymorphisms with Alzheimer's disease: a report on autopsy-confirmed cases.Semantic proximity Read ↗

Association of serum AACT levels and AACT signal polymorphism with late-onset Alzheimer's disease in Northern Ireland.Semantic proximity Read ↗

Plasma angiotensin-converting enzyme in Alzheimer's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.